ReviewJournal of physiology and biochemistry2025
Ceramides in non-communicable diseases: pathways, nutritional modulation, and therapeutic opportunities.
Review in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceramides are sphingolipids formed from fatty acids linked to sphingosine and an amide, which are involved in cellular pathways such as apoptosis, fibrosis, oxidative stress, and inflammation. Six distinct fatty acyl selective ceramide synthases (CerS) produce ceramides. This specific enzymatic modulation can either increase or reduce the production of specific ceramides, which can have either adverse or protective effects, suggesting that enzymatic modulation may serve as a tool for innovative therapy. Specifically, modulation of glucosylceramide synthase, sphingomyelinase, or ceramidase can reverse the generation of potentially apoptotic ceramides, similar to how inhibition of serine palmitoyltransferase or ceramide synthases may be significant in inflammatory conditions by decreasing the generation of inflammatory ceramides. In this context, the modulation of plasma ceramides may represent a protective factor for chronic non-communicable diseases (NCDs), such as cardiovascular diseases, type 2 diabetes, and chronic kidney disease. Previous studies indicate that dietary fat and protein intake influence plasma sphingolipid levels. Therefore, this review aims to discuss the effects of ceramide on patients with NCDs, providing an overview of the influence of nutrition on ceramide levels and outlining future perspectives.
Indexed as
Identifiers
40828428What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.